Join Oryzon Genomics for a virtual KOL Event to briefly review, then discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disorder (BPD), featuring Dyanna Domilici, MD (Adams Clinical, Copley Clinical), who will offer a US PI and clinician perspective, Marc Ferrer, MD, PhD (Vall d’Hebron University Hospital), who will offer an EU PI and clinician perspective, and Sarah Fineberg, MD, PhD (Yale School of Medicine), who will offer a non-PI clinician perspective on the potential clinical and real-world implications for the results.

Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor in Phase IIb in BPD and schizophrenia. PORTICO (EudraCT No.: 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) was a global double-blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial that evaluated the efficacy and safety of vafidemstat in a BPD population. The study recruited a total of 210 patients, randomized 1:1 in two arms, across 27 sites in the US and Europe. The trial had two independent primary endpoints: reduction of agitation and aggression and overall disease improvement in BPD severity.

A live question and answer session will follow the formal presentations.